Loading…
← CockpitCompetitor Analysis › MOVE.SW Medacta Group SAOpen in the cockpit ↗

Medacta Group SAMOVE.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties

Swiss maker of hip and knee joint replacement implants and minimally-invasive surgical instrumentation.

≈ A smaller Swiss Stryker/Zimmer Biomet for joint implantsMomentum laggard 2
Mkt cap
$2.48B
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$5.35M
20-day average traded
Fwd P/E
24.0×
forward earnings
ROIC−WACC
+5.5 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
114 days
12 Mar 2027
Close · CHFCHF 104.80
1D-0.2%
1W-4.7%
1M-9.8%
3M-18.8%
6M-27.6%
YTD-33.0%
1Y-31.1%
ATR %3.4%
52w lowhigh40.9% off high

What Medacta does

Swiss maker of hip and knee joint replacement implants and minimally-invasive surgical instrumentation.

Sells implants and the instrument sets used to place them to hospitals, directly in some markets and through distributors elsewhere, and trains surgeons at its own institute so they adopt its techniques. Hips and knees carry the business. The Siccardi family, which founded it, remains the controlling shareholder.

In one line: A smaller Swiss Stryker/Zimmer Biomet for joint implants.

Products and services

  • Hip implants
  • Knee implants
  • Spine products
  • Sports medicine
  • Surgeon training (M.O.R.E. Institute)

Customers

  • Orthopedic surgeons
  • Hospitals

Where it sits in the supply chain

  • MedTech
  • Orthopedic implants
  • Hip & knee replacement systems

What could go right

  • Aging population raising joint-replacement volumes
  • Minimally invasive technique adoption

What could go wrong

  • Hospital group-purchasing price pressure
  • MDR regulatory compliance costs

Moat: narrow (brand, switching costs, distribution). Surgeon training and technique loyalty (AMIS) create switching costs versus larger rivals.

Headquarters: Castel San Pietro, Switzerland · Founded: 1999 · Employees: 2,165

Named competitors

Medacta at a glance

Size Medacta (MOVE.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $2.48B, the 83rd largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 104.80 on 18 Nov 2026.

Performance Over six months the shares fell 27.6%, against -0.3% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 7.5% over the last twelve months (peer median +4.7%); the operating margin is 14.9% (peer median 7.4%).

Valuation It trades at 24.0× forward earnings against a peer median of 24.3× (8th cheapest of 18).

Capital Return on invested capital runs 5.5 points above its cost of capital (5.6% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 101MOVE.SW 73
Six months, rebased to 100: Medacta against the median of its 20 peers (local-currency closes).

Medacta financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 655MCHF 641MCHF 563MCHF 496MCHF 439M
Revenue growth—+14%+13%+13%—
Gross profitCHF 429MCHF 411MCHF 362MCHF 320MCHF 289M
EBITDACHF 174MCHF 177MCHF 150MCHF 131MCHF 121M
Net incomeCHF 71.5MCHF 89.5MCHF 69.4MCHF 46.0MCHF 46.4M
Free cash flow-CHF 1.60MCHF 27.8MCHF 17.0MCHF 3.78MCHF 10.4M
Capital expenditureCHF 149MCHF 134MCHF 99.7MCHF 79.9MCHF 71.5M
Total debtn/aCHF 244MCHF 229MCHF 189MCHF 170M

Quarterly statements and history in the cockpit →

Medacta competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%EBO002901NEOG300529EKTA-B688029OBCKCELC2276COTNMETNATRCDRW86951ESTAVCYTBONEX688114AFXIRTCMOVE.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Medacta is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%0×100×200×EBO002901NEOG300529EKTA-B688029OBCK2276COTNMETNATRC6951VCYTBONEXAFXIRTCMOVE.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medacta is the large dot.

Medacta competitors and peer comparison

Head to head with its named competitors (MOVE.SW vs ZBH vs SYK vs SN..L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Medacta MOVE.SW$2.48B-28%+8%15%24.0×n/a
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How Medacta compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medacta against its 20 peers (data as of 18 Nov 2026)
MeasureMOVE.SWPeer medianRank in peer set
1-month return-9.8%-3.0%6th lowest of 21
6-month return-27.6%-0.3%4th lowest of 21
Distance from 52-week high-40.9%-27.0%6th lowest of 21
Revenue growth (TTM)+7.5%+4.7%8th highest of 20
Operating margin14.9%7.4%8th highest of 20
Forward P/E24.0×24.3×8th cheapest of 18
ROIC minus cost of capital+5.5 pp-0.7 pp7th highest of 20
EV / EBITDA13.5×17.1×5th cheapest of 13
Net debt / EBITDA1.5×0.4×7th most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%

Questions

Who are Medacta's main competitors?
Named competitors: Zimmer Biomet (ZBH), Stryker (SYK), Smith+Nephew (SN..L), DePuy Synthes (J&J) (JNJ). The cockpit's measured peer set (industry) also includes EBOS (EBO.AX), Double Medical Technology (002901.SZ), Neogen (NEOG), Jafron Biomedical (300529.SZ), Elekta (EKTA-B.ST), Micro-Tech (Nanjing) (688029.SS).
Is Medacta expensive compared with its peers?
On forward p/e it trades at 24.0× against a peer median of 24.3×, 8th cheapest of 18 in its peer set.
How has Medacta stock performed?
Over six months to 18 Nov 2026 the shares returned -27.6% against -0.3% for the median peer; over one year -31.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.